Table 1 Summary of the studies meeting inclusion criteria
From: Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database
| Â | Number (%) of mapping models |
|---|---|
Total | 121 |
Source instrument* | |
Barthel index | 3 (2%) |
28-joint disease activity score (DAS 28) | 3 (2%) |
Dermatology Life Quality Index (DLQI) | 3 (2%) |
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ), all variants | 12 (10%) |
Functional Assessment of Cancer Therapy (FACT), all variants | 5 (4%) |
HAQ (including modified HAQ and HAQ-DI) | 15 (12%) |
Modified Rankin scale (mRS) | 3 (2%) |
Numerical rating scale or visual analogue | 4 (3%) |
Parkinson’s Disease Questionnaire (PDQ-8 & PDQ-39) | 5 (4%) |
Short form variants (SF-6D, SF-12, SF-36) | 13 (11%) |
25-item Visual Functioning Questionnaire (VFQ-25) | 3 (2%) |
Other generic measures | 15 (12%) |
Other condition specific measures | 41 (34%) |
Disease area | |
Cancer | 16 (13%) |
Cardiovascular | 11 (9%) |
Central nervous system | 12 (10%) |
Digestive system | 5 (4%) |
Eye conditions | 3 (2%) |
General population | 16 (13%) |
Mental health and behavioural disorders | 4 (3%) |
Musculoskeletal | 28 (23%) |
Respiratory system | 3 (2%) |
Skin | 3 (2%) |
Various | 14 (12%) |
Other | 6 (5%) |
Sample size (number of observations in the estimation sample, including repeated measurements of the same patients) | Â |
< 200 | 21 (17%) |
200-499 | 16 (13%) |
500-999 | 13 (11%) |
1000-4999 | 27 (22%) |
5000-19,999 | 19 (16%) |
20,000-99,999 | 4 (3%) |
≥ 100,000 | 2 (2%) |
Not clearly stated | 19 (16%) |